Skip to content

Probiotic Study in Alcohol Recovery

Effects of Probiotic Supplementation in Alcohol Use Disorder: A Randomised, Placebo-Controlled Pilot Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07510113
Enrollment
38
Registered
2026-04-03
Start date
2025-12-15
Completion date
2026-04-17
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Keywords

Probiotics, Alcohol use disorder, Gut-brain-axis, Gut health

Brief summary

Alcohol Use Disorder (AUD) is a common condition that can affect physical and mental health. Current treatments do not work for everyone, and new approaches are needed. This study is investigating whether taking a probiotic supplement (a type of "good bacteria") can help reduce alcohol craving and improve psychological, biological, and cognitive wellbeing. Participants are randomly assigned to receive either a probiotic supplement or a placebo (a capsule with no active ingredients) for four weeks. Neither the participants nor the researchers know which treatment is given during the study. The study measures alcohol craving, gastrointestinal composition, thinking and memory, mental health, and eating and drinking behaviour at the start and end of the study. The aim is to understand whether probiotics could be a helpful additional approach to support people with AUD.

Interventions

DIETARY_SUPPLEMENTProbiotic Formula Capsule

A probiotic or placebo is randomly administered to patients with alcohol use disorder

Sponsors

Loughborough University
Lead SponsorOTHER
Innovate UK
CollaboratorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Placebo and probiotics are randomly assigned at the same time in a triple-blinded study design

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A self-reported history of heavy drinking * At least one heavy drinking episode (≥8 units) in the last 28 days

Exclusion criteria

* Participants being under 18 years of age * Supplementation of probiotics or prebiotics within the past 4 weeks * Antibiotic use within the past 4 weeks * Major psychiatric conditions diagnosed e.g., bipolar disorder, schizophrenia * Current pregnancy or breastfeeding * Having had a heavy drinking episode (≥8 units) in the last 12 hours OR a breath alcohol reading above 35 µg/100 ml

Design outcomes

Primary

MeasureTime frameDescription
38 participants with Alcohol Use Disorder assessed for Working Memory by n-back taskFrom enrollment to the end of the treatment at 4 weeksWorking memory will be assessed using a computerized N-back task (1-back, 2-back, 3-back conditions). Participants respond when a stimulus matches one presented previously (1-3 trials earlier). The task includes 50 trials per condition with 10 target stimuli. Each stimulus is presented for 1000 ms. Performance will be measured based on the number of commission errors (count) and number of correct responses (count), with higher correct responses indicating better working memory performance and higher commission errors indicating poorer performance.
38 participants with Alcohol Use Disorder assessed for Gut Microbiome Composition by 16S rRNA Gene SequencingFrom enrollment to the end of the treatment at 4 weeksGut health will be assessed using 16S ribosomal RNA (rRNA) gene sequencing of stool samples collected and analysed in the laboratory. Microbial composition will be characterised using standard bioinformatics pipelines. Outcomes will include alpha diversity (within-sample diversity; e.g., Shannon diversity index) and beta diversity (between-sample differences in microbial composition). Performance will be measured as diversity indices (unitless values) and distance metrics for beta diversity, with higher alpha diversity generally indicating greater microbial diversity and gut health.
38 participants with Alcohol Use Disorder assessed for Alcohol Craving by Penn Alcohol Craving ScaleFrom enrollment to the end of the treatment at 4 weeksAlcohol craving will be assessed using the Penn Alcohol Craving Scale (PACS), a 5-item self-report questionnaire measuring frequency, intensity, and duration of alcohol cravings over the past week. Each item is rated on a scale from 0 to 6, yielding a total score ranging from 0 to 30. Performance will be measured as the total PACS score (range 0-30), with higher scores indicating greater alcohol craving severity.
38 participants with Alcohol Use Disorder assessed for Response Inhibition by Go/No-Go taskFrom enrollment to the end of the treatment at 4 weeksResponse inhibition will be assessed using a computerized Go/No-Go task. Participants are required to respond to "go" stimuli and withhold responses to "no-go" stimuli. Performance will be measured as the number of commission errors (responses during no-go trials; count) and the number of correct responses (correct responses to go trials; count), with higher commission errors indicating poorer response inhibition and higher correct responses indicating better task performance.

Secondary

MeasureTime frameDescription
38 participants with Alcohol Use Disorder assessed for Depression, Anxiety, and Stress by Depression Anxiety Stress Scales-12From enrollment to the end of the treatment at 4 weeksMental health symptoms will be assessed using the Depression Anxiety Stress Scales-12 (DASS-12), a 12-item self-report questionnaire measuring symptoms of depression, anxiety, and stress. Each item is rated on a 4-point Likert scale (0-3), yielding a total score ranging from 0 to 36. Performance will be measured as the total DASS-12 score (range 0-36), with higher scores indicating greater psychological distress.
38 participants with Alcohol Use Disorder assessed for Drinking Behaviour by Loughborough Alcohol Drinking QuestionnaireFrom enrollment to the end of the treatment at 4 weeksDrinking behaviour will be assessed using the Loughborough Alcohol Drinking Questionnaire (LoAD-Q), a 33-item self-report questionnaire measuring three dimensions: emotional drinking, external drinking, and restrained drinking. Each item is rated on a 5-point Likert scale (1 = never to 5 = very often). Subscale scores are calculated by summing item responses within each dimension. The emotional drinking subscale (13 items) has a score range of 13 to 65, the external drinking subscale (10 items) ranges from 10 to 50, and the restrained drinking subscale (10 items) ranges from 10 to 50. Performance will be measured as subscale total scores, with higher scores indicating greater levels of emotional, external, and restrained drinking behaviour, respectively.
38 participants with Alcohol Use Disorder assessed for Attention by Visual Search taskFrom enrollment to the end of the treatment at 4 weeksAttention will be assessed using a computerized visual search task in which participants identify target stimuli among distractors. Performance will be measured as reaction time (milliseconds) and accuracy (percentage of correct responses, %) across trials, with lower reaction times indicating better attentional performance and higher accuracy indicating better task performance.
38 participants with Alcohol Use Disorder assessed for Cognitive Bias by Rough Estimation TaskFrom enrollment to the end of the treatment at 4 weeksCognitive bias will be assessed using the Rough Estimation Task (REsT), where participants read a list of alcohol-related, semantically related, and unrelated words and estimate the proportion of alcohol-related words. Performance will be measured as the percentage (%) of words estimated as alcohol-related, with overestimation (\>33%) indicating cognitive bias.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026